Roche to announce big expansion in Arizona; Startup Redx gains launch funds;

 @FierceBiotech: Pfizer lung cancer drug looks promising in mid-stage study. Report | Follow @FierceBiotech

 @JohnCFierce: Innovative biotech companies learn by listening to staffers. Article | Follow @JohnCFierce

> The Arizona Daily Star is reporting that Roche will soon announce that it is bringing up to 500 staffers to a biotech research campus in the state. A little more than two years after Roche bought out Ventana Medical Systems, economic development officials say they've been in close contact with the pharma giant as it hatches plans for a big expansion. The move is a coup for the state, which has been working hard to make Innovation Park into a major biomedical research hub. Sanofi already has a site on the campus and state officials are beavering away at bringing in more companies. Report

> Venture capitalist Jon Moulton has put up part of the $2.5 million being used to launch Redx Pharma, a UK startup promising to develop new therapies that can be licensed out to innovation-hungry pharma companies. Story

> Cel-Sci has won permission to start clinical trials for head and neck cancer in Taiwan. Report

> Dutch biotech Prosensa won a £7.5 million milestone payment from GlaxoSmithKline. Prosensa release

> Cellectis bioresearch has established a US subsidiary at the Cambridge Innovation Center in Cambridge, Massachusetts. Cellectis release

And Finally... A study by Christopher Hopwood and colleagues at Michigan State calls for a "more scientific and practical method of categorizing personality disorders--a proposal that ultimately could improve treatment." Release

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.